196 results about "Nonhuman animal" patented technology

The invention discloses a construction method and application of an NMD escape model of an Alport syndrome mouse. A non-human animal model carrying Col4a5 gene c.4432delG frame shift mutation is prepared on the basis of a CRISPR / Cas9 gene editing technology. The method comprises the following steps: co-injecting gRNA of a 49 exon of a targeted Col4a5 gene, homologous recombinant donor oligonucleotide containing c.4432delG mutation and Cas9 nuclease into a mouse fertilized egg, and carrying out embryo transplantation to obtain an F0-generation mutant mouse; a mutation site is verified by combining PCR (Polymerase Chain Reaction) with sequencing, and a stably inherited mutation line is established through two generations of breeding. Through verification, the model accords with pathological characteristics of the Alport syndrome, can stably simulate typical clinical manifestation and pathological characteristics of the human X-linked Alport syndrome, and can be used as an important tool for research of the Alport syndrome.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

Provided herein are personalized wellness systems for non-human subjects, such as a companion animal, that utilize a machine learning model to analyze genetic data and phenotypic data of the non-human subjects and make a product or behavioral recommendation for the non-human subjects based, at least in part, on the analysis. The personalized wellness systems may include an Application (App) or website for use by a guardian or medical healthcare professional of the non-human subject to monitor the health and wellness of the non-human animal and receive notifications regarding the recommended products or behavioral modifications. The machine learning model may also analyze environmental data, behavioral, clinical data, and activity data to generate new recommendations or refine existing recommendations for the non-human subject.

The invention relates to a method for constructing a male non-human animal nicotine exposure model, which comprises the following steps: dissolving and extracting contents in a nicotine bag to obtain a nicotine bag content extracting solution; and selecting a male non-human animal, and performing intragastric administration with the nicotine bag content extracting solution to construct the male non-human animal nicotine exposure model. The invention also relates to a nicotine pocket reproductive development safety evaluation method based on the male non-human animal. The method comprises the following steps: taking the male non-human animal nicotine exposure model as a male parent to mate with a normal female non-human animal to generate a filial generation; detecting a parent reproduction index and a filial generation development index; and performing nicotine pocket reproductive development safety evaluation according to the male parent reproductive index and the offspring development index. The nicotine bag reproductive development safety evaluation comprises comparison with a nicotine bag safety standard substance.

The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.

The present disclosure provides a method of evaluating a mechanism of bipolar disorder, in particular mood switch, in human-derived neurons which may include providing a mechanism of an attenuated protein interaction of CaV1.2 and BK that can cause the calcium signaling deficit, the main cellular phenotype. The present disclosure further provides a method of evaluating a composition for efficacy in treating bipolar disorder, including providing a genetically modified mouse exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified mouse animal to a mild stressor; and determining whether the genetically modified mouse animal experiences a behavioral switch. The present disclosure also provides a method of treating bipolar disorder in a subject in need thereof, including administering to the subject a therapeutically effective amount of a BK channel agonist.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The application provides a construction system and device of a non-human animal model of tension pneumothorax, and the system comprises: a fixing unit for fixing the non-human animal; a first processing unit for puncturing a puncture needle to the parietal pleura, making a guide wire pass through the needle cavity of the puncture needle to enter the pleural cavity, and withdrawing the puncture needle; a second processing unit for inserting a catheter along the guide wire to make the catheter enter the pleural cavity, pulling out the guide wire, and fixing the catheter; a third processing unit for unidirectional air injection into the pleural cavity through the catheter; and a fourth processing unit for monitoring the range of pneumothorax, determining that the non-human animal model of tension pneumothorax is obtained when the lung sliding of the injection side chest is greater than or equal to 4 / 6 area and lung points are observed, stopping air injection, and obtaining the non-human animal model of tension pneumothorax. The construction success rate of the application is 100%, the construction process is rapid, repeatable and objective in determination, and the application can provide a rapid and repeatable platform for diagnostic research, decompression technology evaluation and training.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

Technical Problem The purpose of the present invention is to provide a method which enables sex selection in a non-human animal, and enables a coming individual to have no recombination gene, and a transgenic non-human animal giving birth to individuals of only one sex, which is used in the method.Solution to Problem The present disclosure relates to a male transgenic non-human animal in which one of an X chromosome and a Y chromosome comprises an exogenous embryonic death induction gene operatively connected to a drug-responsive promoter. The present disclosure also includes a method for producing a male transgenic non-human animal for sex selection.

Provided are genetically modified animals and cells with humanized NKC and / or Ly49 locus. In one aspect, the genetically-modified, non-human animal comprises at an endogenous NKC locus, one or more human NKC genes, and / or at an endogenous Ly49 locus, one or more human KIR genes. In some embodiments, the animal comprises an endogenous Clec1b gene. In one aspect, the animal comprises at a safe harbor locus (e.g., an endogenous Hipp11 orRosa26 gene locus), one or more human KIR genes.

To provide a humanized rodent that expresses a heavy chain containing a VL domain. [Solution] A non-human animal, tissue, cell, and genetic material is provided which includes a modification of an endogenous non-human heavy chain immunoglobulin sequence and contains functional ADAM6 activity in a rodent (e.g., mouse), wherein the non-human animal rearranges the human immunoglobulin light chain gene segment in relation to the heavy chain constant domain and expresses an immunoglobulin-like molecule which contains a human immunoglobulin light chain variable domain fused to the heavy chain constant domain and is a cognitive of a human immunoglobulin light chain variable domain fused to the light chain constant domain.

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.

Non-human animals (and / or non-human cells) and methods of using and making the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Igλ light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

Disclosed is a vaccine for non-human animals, which vaccine enables effective immune induction in non-human animals such as livestock or poultry. The vaccine for non-human animals of the present invention comprises liposomes each comprising an antigen molecule(s) bound to the surface thereof, the antigen molecule(s) being derived from a pathogen infectious to the non-human animals. The non-human animals are, for example, livestock or poultry. One most preferred example of the vaccine according to the present invention is an infectious bronchitis virus (IBV) vaccine, which is effective against various isolated IBV strains, and which is expected to be sufficiently applicable even to cases where a mutant strain appeared. Another preferred example of the vaccine according to the present invention is a PRRSV vaccine, which was confirmed to have an effect that reduces fever, lung lesion development, and the like caused by the infection. The present invention enables development of liposome vaccines effective for prevention of infections caused by various non-human animal pathogens including PRRSV as well as IBV.

The present disclosure provides feed compositions comprising a basal animal diet supplemented with dimethylglycine. The feed compositions improve growth performance, livability, carcass characteristics, and milk quality in non-human animals fed the feed compositions.

The present invention provides a non-human animal having a novel fiber and a method for preparing the non-human animal. Specifically, the present invention provides a non-human animal with reduced expression or functions of at least one gene constituting the Krt or KAP family, and a method for preparing the non-human animal.

A genetically modified non-human animal in which an auxin-inducible degron system controls degradation of a target protein in a living body includes: a chromosome containing a first nucleic acid that encodes a mutant TIR1 family protein having a mutation at an auxin-binding site and having affinity to an auxin analog.

The invention provides a variety of novel devices, systems, and methods of utilizing mixed-ionic-electronic conductor (MIEC) materials adapted to function with an applied current or potential. The materials, as part of a circuit, are placed in contact with a part of a human or nonhuman animal body. A sodium selective membrane system utilizing the MIEC is also described.

Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification and characterization of microbiota may include identifying and characterizing the microbiota of potential donors, characterizing the potential donors, and identifying potentially therapeutic microbiota based on analysis of such data from multiple individuals. In some embodiments, the identification and characterization of microbiota may include testing, that is, administering microbiota of potential donors to animals suffering from a disease or condition, documenting any therapeutic response, and optionally identifying and characterizing the microbiota of recipients before and after treatment, and optionally identifying demonstrated therapeutic microbiota. Embodiments of the invention encompass compositions comprising the microbiotia, including solid oral compositions, methods of making these compositions, and methods of treatment of non-human animals suffering from various diseases and conditions with these compositions.